T12	Subject 120 157	patients with nonmyeloid malignancies
T16	Treat-Disorder 211 267	postchemotherapy platelet nadirs of < or = 20,000/microL
T11	Treatment 38 116	recombinant human interleukin-11 (rhIL-11, also known as oprelvekin [Neumega])
T17	Sub-Disorder 134 157	nonmyeloid malignancies
T13	Drug 38 70	recombinant human interleukin-11
T15	Potential_therapeutic_event 200 210	preventing
E1	Potential_therapeutic_event:T15 
